Historic Price Surge and Market Outperformance
On 23 Jul 2026, Parmax Pharma’s stock opened with a 2.00% gain and maintained this level throughout the trading session, touching an intraday high of Rs.109.20. This price represents both the new 52-week and all-time high for the stock, underscoring a significant appreciation from its 52-week low of Rs.22.60. The stock’s current price is 383.19% above this low, highlighting an extraordinary rally over the past year.
Parmax Pharma has outperformed its sector and the broader market consistently. On the day of the record high, the stock outpaced the Pharmaceuticals & Biotechnology sector by 1.69%, while the Sensex declined by 0.15%. Over the past week, the stock gained 10.37% compared to the Sensex’s 0.71% decline. The one-month return stands at an impressive 51.31%, dwarfing the Sensex’s modest 0.58% rise.
More strikingly, the stock has delivered a 246.56% return over the last three months and a 176.53% gain over the past year, while the Sensex fell by 1.32% and 7.35% respectively during these periods. Year-to-date, Parmax Pharma’s stock has surged 222.79%, contrasting with the Sensex’s 10.07% decline. Even over a five-year horizon, the stock has doubled with a 101.85% gain, outperforming the Sensex’s 44.67% rise.
Consistent Uptrend and Technical Strength
The stock has been on a consecutive gain streak for 21 trading days, delivering a cumulative return of 51.31% during this period. This sustained momentum is supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust bullish trend.
Technical indicators further reinforce this positive outlook. The overall technical trend is classified as bullish, a status that was upgraded on 8 Jun 2026 when the stock was trading at Rs.48.81. Weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory indicators all reflect bullish signals. Although the Relative Strength Index (RSI) remains bearish on both weekly and monthly charts, the dominant technical momentum remains positive.
Key support and resistance levels provide additional context: the immediate support is at Rs.22.60, the 52-week low, while the immediate resistance was previously at Rs.89.37 (20-day moving average area). The stock has decisively surpassed these levels to reach the current all-time high of Rs.109.20.
Valuation and Financial Metrics
Despite the impressive price performance, Parmax Pharma remains a loss-making entity, with valuation multiples reflecting this status. The price-to-earnings ratio (TTM) is not applicable due to losses, and the price-to-book value stands at -6.51x. Enterprise value multiples such as EV/EBITDA and EV/EBIT are negative at -14.22x and -11.07x respectively, while EV/Sales is 4.21x and EV/Capital Employed is 10.79x.
The company does not currently pay dividends, with no dividend yield or payout reported. The absence of dividend distribution aligns with its financial performance and reinvestment strategy.
Quality and Financial Trend Assessment
Parmax Pharma’s overall quality grade is below average, reflecting challenges in long-term financial performance. Key quality factors include a 5-year sales decline of 14.30% and a 5-year EBIT contraction of 225.63%. The company maintains a net cash position with negative net debt to equity of -1.77, indicating minimal leverage. Management risk, growth, and capital structure are all rated below average.
Short-term financial trends remain negative as of March 2026, with net sales over the latest six months declining by 31.23% to Rs.7.64 crores and profit after tax for nine months shrinking by 50.12% to a loss of Rs.3.39 crores. Despite these figures, the company reported its highest quarterly earnings per share at a loss of Rs.-1.55, indicating some improvement in earnings performance.
Trading Volumes and Market Activity
Delivery volumes have shown a positive trend, with a 31.22% increase over the past month and a substantial 71.62% rise in delivery volume on the day of the record high compared to the 5-day average. This suggests heightened trading interest and liquidity in the stock during this period of price appreciation.
Summary of Market Capitalisation and Ratings
Parmax Pharma is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector. The MarketsMOJO Mojo Score stands at 31.0, with a current Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 8 Jun 2026. This reflects a cautious stance on the stock despite its recent price gains.
Conclusion
Parmax Pharma Ltd’s stock reaching an all-time high of Rs.109.20 on 23 Jul 2026 marks a significant milestone in its market journey. The stock’s strong performance over multiple time frames, supported by a sustained bullish technical trend and consistent gains, highlights a remarkable phase for the company. While financial and quality metrics indicate areas of concern, the market has rewarded the stock with substantial appreciation, reflecting a complex but noteworthy trajectory in the Pharmaceuticals & Biotechnology sector.
